Showing 5,601 - 5,620 results of 6,579 for search '(( significant decrease decrease ) OR ( significant ((17 decrease) OR (a decrease)) ))~', query time: 0.64s Refine Results
  1. 5601
  2. 5602
  3. 5603
  4. 5604

    Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
  5. 5605

    Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

    Published 2025
    “…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
  6. 5606

    Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
  7. 5607

    Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

    Published 2025
    “…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
  8. 5608

    Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

    Published 2025
    “…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”
  9. 5609

    Source Apportionment of Atmospheric Iron in Northern China Based on Three-Year Continuous Measurements by Tianle Zhang (21796679)

    Published 2025
    “…Results showed nearly 50% of Fe originated from anthropogenic sources, primarily industrial processes (30%) and coal combustion (17%). Although PM<sub>2.5</sub> concentrations decreased significantly, the Fe component of PM<sub>2.5</sub> did not show a significant decline. …”
  10. 5610
  11. 5611
  12. 5612
  13. 5613
  14. 5614
  15. 5615
  16. 5616
  17. 5617
  18. 5618

    Supplementary file 1_Analysis of gut and circulating microbiota characteristics in patients with liver cirrhosis and portal vein thrombosis.docx by Ping Qi (772738)

    Published 2025
    “…</p>Results<p>(1) Gut microbiota showed no α-diversity difference between groups, but β-diversity differed significantly. PVT patients had increased Gram-negative bacteria (such as Escherichia-Shigella) and decreased SCFA-producing taxa. (2) Compared with peripheral vein microbiota, portal vein microbiota showed significant difference in α diversity and β diversity in cirrhotic patients with PVT, with Massilia enriched. (3) Portal microbiota had the highest diagnostic value for PVT (AUC = 0.95). (4) The tPVT group had more portal-feces shared genera than the tNPVT group (49 vs. 29). …”
  19. 5619
  20. 5620